To search for drugs that could have synergistic effects on liver cancer with donafenib, we selected 657 small molecule inhibitors from the CTPR, GDSC, and PRISM databases,[27, 28, 29, 30, 31] which involve various well‐known signaling pathways in cells, including the apoptosis, PI3K‐AKT, MAPK, and autophagy pathways (Figure 1A and Table S1, Supporting Information). Here, AKT1 is linked to liver cancer.